Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Tissue-Penetrating Light Releases Chemotherapy inside Cancer Cells

By BiotechDaily International staff writers
Posted on 02 Mar 2014
Researchers have developed an advanced way of using light to convey chemotherapy safely to cancer cells. A light-activated drug delivery system is particularly promising, because it can accomplish spatial and temporal control of drug release.

Drs. Jeffrey Zink, professor of chemistry and biochemistry, and Fuyu Tamanoi, professor of microbiology, immunology, and molecular genetics, and colleagues, from the University of California, Los Angeles’ (UCLA) Jonsson Comprehensive Cancer Center (JCCC; Los Angeles, USA) published their findings February 20, 2014, in the journal Small.

Finding ways to deliver and release anticancer drugs in a controlled way that only targets the tumor can greatly decrease the amount of side effects from treatment, and greatly increase the cancer-killing efficacy of the drugs. The challenges of treating cancer frequently comes from the difficulty of getting anticancer chemotherapy drugs to tumor cells without damaging healthy tissue in the process. Many cancer patients experience treatment side effects that are the result of drug exposure to healthy tissues.

A major challenge in the development of light-activated drug delivery is to design a system that can respond to tissue-penetrating light. Drs. Tamanoi and Zink joined their diverse teams and collaborated with Dr. Jean-Olivier Durand at University of Montpellier, France to develop a new type of microscopic particles (nanoparticles) that can absorb energy from tissue-penetrating light that releases pharmaceutical agents in cancer cells.

These new nanoparticles are armed with specially designed nanovalves that can control release of anticancer drugs from thousands of pores, or tiny tubes, which hold molecules of chemotherapy drugs within them. The ends of the pores are blocked with capping molecules that hold the drug in similar to a cork in a bottle. The nanovalves contain special molecules that respond to the energy from two-photon light exposure, which opens the pores and releases the anticancer drugs. The performance of the nanoparticles was demonstrated in the laboratory using human breast cancer cells.

Because the effective depth range of the two-photon laser in the infrared red wavelength can reach 4 cm from the skin surface, this delivery system is best suited for tumors that can be reached within that range, which possibly include stomach breast, colon, and ovarian cancers.

Another facet of the nanoparticles is that they are fluorescent and therefore can be monitored in the body with molecular imaging techniques. This allows the researchers to track the progress of the nanoparticle into the cancer cell to safeguard that it is in its target before light activation. This ability to track a targeted therapy to its target has been called “theranostics” in the scientific nomenclature. “We have a wonderful collaboration,” said Dr. Zink. “When the JCCC brings together totally diverse fields, in this case a physical chemist and a cell signaling scientist, we can do things that neither one could do alone.”

“Our collaboration with scientists at Charles Gerhardt Institute was important to the success of this two-photon activated technique,” said Dr. Tamanoi. “It provides controls over drug delivery to allow local treatment that dramatically reduces side effects.”

Related Links:

University of California, Los Angeles’ Jonsson Comprehensive Cancer Center




Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.